Prescription patterns for children with juvenile idiopathic arthritis in Michigan Medicaid: a comparison by

Meredith P Riebschleger1, Heather A Van Mater2, Lisa M Cohn1

  • 1Division of Pediatric Rheumatology, Child Health Evaluation and Research Unit, University of Michigan, 6C15A NIB, 300 North Ingalls, Ann Arbor, MI 48109 USA.

Insights

Pediatric rheumatologists are scarce, leading to varied care for juvenile idiopathic arthritis (JIA). Non-specialist care was linked to less use of advanced medications like disease-modifying anti-rheumatic drugs (DMARDs) and biologics.

Area of Science:

  • Pediatric Rheumatology
  • Health Services Research

Background:

  • Limited pediatric rheumatologists in the US necessitate care from diverse physician types.
  • Care variations among different physician groups for pediatric rheumatologic diseases are not well understood.

Purpose of the Study:

  • To compare medication claims for children with juvenile idiopathic arthritis (JIA) based on the type of physician prescribing.

Main Methods:

  • Retrospective cohort study using Michigan Medicaid data (2005-2007).
  • Analysis included 397 children with JIA, examining medication claims by prescriber type (internist, pediatric rheumatologist, non-rheumatologist).

Main Results:

  • No significant difference in overall medication claim frequency between internists and pediatric rheumatologists.
  • Children with non-rheumatologist prescribers were less likely to receive disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents.

Conclusions:

  • The observed differences in DMARD and biologic agent use highlight the importance of specialized pediatric rheumatology care.
  • Referral to pediatric rheumatologists is crucial for optimal management of JIA.
Abstract

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...